BioTime to Present Animal Research On Eliminating Battlefield Transfusions.Business Editors & Health/Medical Writers Experimental Biology 2002 BIOWIRE2K BERKELEY, Calif.--(BW HealthWire)--Feb. 27, 2002 BioTime, Inc. (AMEX AMEX See: American Stock Exchange :BTX (Balanced Technology EXtended) A motherboard design from Intel introduced in 2004 that supersedes the ATX. Unlike the ATX, the placement of all chip sockets in the BTX is defined in order to provide sufficient air flow over the processor and display adapter. ) announced today that it has completed animal studies that may serve as a model for the elimination of donor blood transfusions during the treatment of battlefield trauma. The studies show that BioTime's plasma expander can allow resuscitation resuscitation /re·sus·ci·ta·tion/ (-sus?i-ta´shun) restoration to life of one apparently dead. cardiopulmonary resuscitation without subsequent blood transfusion in rats despite extended periods of hemorrhagic shock hemorrhagic shock n. Hypovolemic shock resulting from acute hemorrhage and characterized by hypotension, tachycardia, oliguria, and by pale, cold, and clammy skin. and respiratory arrest caused by an otherwise lethal loss of half their circulating blood volume. The rats were either ventilated ven·ti·late tr.v. ven·ti·lat·ed, ven·ti·lat·ing, ven·ti·lates 1. To admit fresh air into (a mine, for example) to replace stale or noxious air. 2. with 100% oxygen or maintained in BioTime's proprietary small animal hyperbaric oxygen hyperbaric oxygen n. Oxygen at a pressure that is above one atmosphere. Also called high-pressure oxygen. Hyperbaric oxygen chamber following resuscitation with plasma expander. Other experiments indicated that rats could survive loss of nearly all their blood if, as they lost blood, it was replaced with plasma expander. After 85-89% of their circulating blood was replaced by plasma expander, they were maintained under progressively lower pressures of hyperbaric oxygen. The rats then regenerated new blood and were returned to their cages. Even when 95-98% of their circulating blood was replaced with plasma expander, they could be maintained in oxygen under higher pressure for several hours. However, in these procedures, their own blood had to be transfused back immediately following depressurization. "One additional factor which may have permitted survival following massive hemorrhage and long periods of respiratory arrest was hypothermia hypothermia Abnormally low body temperature, with slowing of physiological activity. It is artificially induced (usually with ice baths) for certain surgical procedures and cancer treatments. ," said Dr. Mark A. Voelker, BioTime's director of bioengineering. "BioTime's proprietary hyperbaric oxygen chamber can keep these animals cool, or warm them while they revive. Previous studies with BioTime's plasma expander have shown that animals can revive after their circulating blood volume is totally replaced under profound hypothermic conditions, even following massive hemorrhage." "Various groups under the sponsorship of military and civilian agencies are also studying fluids and protocols to be used during surgery or in combat and mass casualty conditions when blood products may not be available in the quantities needed," said Dr. Paul Segall, BioTime board chairman and chief executive officer. "Recent events have intensified interest in the area of fluid resuscitation fluid resuscitation Critical care medicine The infusion of isotonic IV fluids to a hypotensive Pt with trauma; aggressive FR may disrupt thrombi, ↑ bleeding, and ↓ survival , the major focus of BioTime's product development program." BioTime's studies have been accepted and are scheduled for presentation at Experimental Biology 2002, the upcoming meeting of the Federation of American Societies for Experimental Biology The Federation of American Societies for Experimental Biology, or FASEB, is a non-profit federation of 21 societies for biomedical research in the United States. Its mission statement is "to advance biological science through collaborative advocacy for research policies that to be held during April 20-24, 2002 in New Orleans. BioTime, headquartered in Berkeley, California develops blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Information about BioTime can be found on the web at www.biotimeinc.com. The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of BioTime products; BioTime's ability to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and foreign regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime's products; BioTime's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in BioTime products; the availability of reimbursement for the cost of BioTime products (and related treatment) from government health administration authorities, private health coverage insurers and other organizations; and the ability of BioTime to raise additional capital. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion